Chandler Robinson - Dec 31, 2024 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role: Chief Executive Officer, Director
Signature: /s/ Karthik Radhakrishnan, Attorney-in-fact
Stock symbol: MNPR
Transactions as of: Dec 31, 2024
Transactions value $: -$48,598
Form type: 4
Date filed: 1/2/2025, 06:14 PM
Previous filing: Oct 2, 2024
Next filing: Mar 7, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MNPR	Common Stock	Options Exercise		+4.9K	+8.72%		61.1K	Dec 31, 2024	Direct	F1
transaction	MNPR	Common Stock	Tax liability	-$48.6K	-2.21K	-3.62%	$22.00	58.8K	Dec 31, 2024	Direct	F2
holding	MNPR	Common Stock						856K	Dec 31, 2024	See Footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MNPR	Restricted Stock Units	Options Exercise	$0	-4.9K	-16.44%	$0.00	24.9K	Dec 31, 2024	Common Stock	4.9K		Direct	F1, F4, F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired on vesting and settlement of restricted stock units.
F2	Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3	As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 855,589 shares. Dr. Robinson disclaimsbeneficial ownership of the 855,589 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
F4	On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5	On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F6	On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.